Surgical Oncology

Adjuvant osimertinib is the reference standard for resected EGFR‑mutant NSCLC

Adjuvant osimertinib now represents the most mature perioperative strategy for resected EGFR‑mutant NSCLC with durable DFS and survival signals from ADAURA. Other third‑generation TKIs and neoadjuvant/perioperative osimertinib approaches show encouraging early efficacy but lack mature EFS/OS data. Key unresolved questions include the role of adjuvant chemotherapy in the osimertinib era and the utility of MRD to personalize perioperative care. 1

Framework for estimands and handling missing PROs in oncology trials

The authors present a practical framework to define estimands and handle progression as an intercurrent event for longitudinal PRO endpoints. They compare hypothetical versus treatment‑policy strategies and demonstrate implementations (implicit MI, joint modelling, control‑based MI) in a simulated trial. Supplementary analyses are recommended to test robustness and support interpretable PRO treatment effects despite missing data. 2

MySurgeryRisk validated for ICU admission, MV, AKI, and in‑hospital death

In 508,097 major inpatient operations across 14 institutions, MySurgeryRisk achieved AUROCs of 0.93–0.95 for ICU admission, MV, AKI, and in‑hospital mortality. Primary procedure codes and clinician‑specific factors were the most influential predictors across sites. The model used routinely collected EHR variables and maintained performance when applied multicentrically, supporting scalability in large health systems. 3